Oppenheimer Asset Management Inc. Buys 44,270 Shares of Certara, Inc. (NASDAQ:CERT)

Oppenheimer Asset Management Inc. raised its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 25.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 221,550 shares of the company's stock after buying an additional 44,270 shares during the period. Oppenheimer Asset Management Inc. owned about 0.14% of Certara worth $2,193,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its position in Certara by 3.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after acquiring an additional 823 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares during the last quarter. Bank of Montreal Can lifted its stake in Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after purchasing an additional 1,670 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its position in shares of Certara by 20.5% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock valued at $138,000 after purchasing an additional 2,202 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Trading Down 0.4%

Shares of NASDAQ CERT traded down $0.04 during mid-day trading on Friday, hitting $11.38. The stock had a trading volume of 2,205,514 shares, compared to its average volume of 1,430,788. The business has a 50 day moving average price of $11.99 and a two-hundred day moving average price of $11.85. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.78 and a current ratio of 2.78. The firm has a market cap of $1.85 billion, a P/E ratio of -569.00 and a beta of 1.44.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company's revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. On average, equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of recent research reports. Robert W. Baird boosted their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Stephens reissued an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Finally, KeyCorp upped their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.67.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.